Evaluation of CYP2C19 Activity Using Microdosed Oral Omeprazole in Humans

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2022 Mar 3

PMID 35238961

Authors

Annika Elbe

Kathrin Isabelle Foerster

Antje Blank

Peter Rose

Jurgen Burhenne

Walter Emil Haefeli

Gerd Mikus

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the suitability of microdosed oral omeprazole for predicting CYP2C19 activity in vivo in combination with simultaneous assessment of CYP3A and CYP2D6 activity using both microdosed midazolam and yohimbine.

Methods: An open, fixed-sequence study was carried out in 20 healthy participants. Single microdosed (100 µg) and therapeutic (20 mg) doses of omeprazole were evaluated without comedication and after administration of established CYP2C19 perpetrators fluconazole (inhibition) and rifampicin (induction). To prevent degradation of the uncoated omeprazole microdose, sodium bicarbonate buffer was administered. The pharmacokinetics of omeprazole and its 5-hydroxy-metabolite were assessed as well as the pharmacokinetics of midazolam and yohimbine to estimate CYP3A4 and CYP2D6 activity.

Results: Calculated pharmacokinetic parameters after administration of 100 µg and 20 mg omeprazole in healthy subjects suggest dose proportionality. Omeprazole clearance was significantly decreased by fluconazole from 388 [95% CI: 266-565] to 47.2 [42.8-52.0] mL/min after 20 mg omeprazole and even further after 100 µg omeprazole (29.4 [24.5-35.1] mL/min). Rifampicin increased CYP2C19-mediated omeprazole metabolism. The omeprazole hydroxylation index was significantly related to omeprazole clearance for both doses. Both fluconazole and rifampicin altered CYP3A4 activity whereas no change of CYP2D6 activity was observed at all.

Conclusions: Microdosed oral omeprazole is suitable to determine CYP2C19 activity, also during enzyme inhibition and induction. However, the administration of sodium bicarbonate buffer also had a small influence on all victim drugs used.

Trial Registration: EudraCT: 2017-004270-34.

Citing Articles

Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers.

Rohr B, Krohmer E, Foerster K, Burhenne J, Schulz M, Blank A Clin Pharmacokinet. 2024; 63(4):469-481.

PMID: 38393578 PMC: 11052790. DOI: 10.1007/s40262-024-01350-x.

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.

Stemkens R, de Jager V, Dawson R, Diacon A, Narunsky K, Padayachee S Antimicrob Agents Chemother. 2023; 67(10):e0068323.

PMID: 37768317 PMC: 10583668. DOI: 10.1128/aac.00683-23.

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults.

Muhareb A, Blank A, Meid A, Foerster K, Stoll F, Burhenne J Clin Pharmacokinet. 2023; 62(9):1305-1314.

PMID: 37505445 PMC: 10450012. DOI: 10.1007/s40262-023-01287-7.

References

Geist M, Bardenheuer H, Burhenne J, Mikus G . Alteration of drug-metabolizing enzyme activity in palliative care patients: Microdosed assessment of cytochrome P450 3A. Palliat Med. 2019; 33(7):850-855. DOI: 10.1177/0269216319843629. View

Hohmann N, Kocheise F, Carls A, Burhenne J, Haefeli W, Mikus G . Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br J Clin Pharmacol. 2015; 79(2):278-85. PMC: 4309633. DOI: 10.1111/bcp.12502. View

Vay M, Meyer M, Blank A, Skopp G, Rose P, Tzvetkov M . Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial. Clin Pharmacokinet. 2020; 59(7):927-939. PMC: 7329762. DOI: 10.1007/s40262-020-00862-6. View

Chang M, Dahl M, Tybring G, Gotharson E, Bertilsson L . Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics. 1995; 5(6):358-63. DOI: 10.1097/00008571-199512000-00004. View

Kimura M, Ieiri I, Wada Y, Mamiya K, Urae A, Iimori E . Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. Br J Clin Pharmacol. 1999; 47(1):115-9. PMC: 2014196. DOI: 10.1046/j.1365-2125.1999.00858.x. View

Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E . Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 2007; 83(2):322-7. DOI: 10.1038/sj.clpt.6100291. View

Hicks J, Swen J, Thorn C, Sangkuhl K, Kharasch E, Ellingrod V . Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013; 93(5):402-8. PMC: 3689226. DOI: 10.1038/clpt.2013.2. View

Katzenmaier S, Markert C, Riedel K, Burhenne J, Haefeli W, Mikus G . Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. Clin Pharmacol Ther. 2011; 90(5):666-73. DOI: 10.1038/clpt.2011.164. View

Burhenne J, Halama B, Maurer M, Riedel K, Hohmann N, Mikus G . Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem. 2012; 402(7):2439-50. DOI: 10.1007/s00216-011-5675-y. View

10.

Elliott P, Dundee J, Elwood R, Collier P . The influence of H2 receptor antagonists on the plasma concentrations of midazolam and temazepam. Eur J Anaesthesiol. 1984; 1(3):245-51. View

11.

Backman J, Olkkola K, Neuvonen P . Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther. 1996; 59(1):7-13. DOI: 10.1016/S0009-9236(96)90018-1. View

12.

Zimmermann T, Yeates R, Riedel K, Lach P, Laufen H . The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole. Int J Clin Pharmacol Ther. 1994; 32(9):491-6. View

13.

Sim S, Risinger C, Dahl M, Aklillu E, Christensen M, Bertilsson L . A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006; 79(1):103-13. DOI: 10.1016/j.clpt.2005.10.002. View

14.

Wienkers L, Wurden C, Storch E, Kunze K, Rettie A, TRAGER W . Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos. 1996; 24(5):610-4. View

15.

Zhou H . CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase. Clin Chim Acta. 2001; 313(1-2):203-8. DOI: 10.1016/s0009-8981(01)00696-9. View

16.

Wedlund P . The CYP2C19 enzyme polymorphism. Pharmacology. 2000; 61(3):174-83. DOI: 10.1159/000028398. View

17.

Niemi M, Backman J, Fromm M, Neuvonen P, Kivisto K . Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet. 2003; 42(9):819-50. DOI: 10.2165/00003088-200342090-00003. View

18.

Kanebratt K, Diczfalusy U, Backstrom T, Sparve E, Bredberg E, Bottiger Y . Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther. 2008; 84(5):589-94. DOI: 10.1038/clpt.2008.132. View

19.

Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J . Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. 2010; 69(3):222-30. PMC: 2829691. DOI: 10.1111/j.1365-2125.2009.03578.x. View

20.

Shah B, Parmar S, Mahajan S, Mehta A . An insight into the interaction between clopidogrel and proton pump inhibitors. Curr Drug Metab. 2012; 13(2):225-35. DOI: 10.2174/138920012798918390. View